Harmony Biosciences Holdings

Healthcare · Biotechnology

41.30$ +0.2% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

Harmony Biosciences Holdings (HRMY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 261 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement HRMY
Line item	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	160	168	155	173	186	201	185	200	239	244	215	261	960
Cost of Revenue	32	43	27	32	43	54	32	38	60	69	45	63	236
Gross Profit	128	125	127	141	143	147	153	162	180	175	171	198	724
Research & Development	17	30	22	64	25	35	35	50	55	50	69	47	221
Selling, General & Administrative	23	28	26	27	29	29	31	34	30	58	33	28	148
Total Operating Expenses	63	85	75	119	82	91	96	114	114	137	134	109	493
Operating Income	65	40	52	21	62	56	56	48	65	39	37	89	231
Interest Expense	7.0	4.8	4.5	4.4	4.3	4.2	3.8	3.6	3.6	3.5	3.2	3.1	13
Pre-Tax Income	52	40	52	22	62	56	57	50	67	41	40	93	241
Income Tax Expense	13	13	13	10	16	6.7	12	9.9	17	18	7.2	18	60
Net Income	38	27	38	12	46	49	46	40	51	22	32	75	181
EBITDA	65	61	62	32	72	66	67	59	73	52	49	102	276

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings